Ozempic And Wegovy May Help Slow Cancer Spread, New Research Suggests

Drugs originally developed to treat type 2 diabetes, including Ozempic and Wegovy, may help slow the progression of several common cancers, according to new research. The medications belong to the GLP-1 class, which has rapidly gained popularity worldwide as a highly effective treatment for obesity and weight management.

The study suggests that patients taking GLP-1 drugs were less likely to develop metastatic, or stage 4, cancer in several major tumor types. Researchers say the findings add to growing evidence that metabolic health, obesity and cancer progression may be more closely connected than previously understood.

What the study examined

The analysis was presented through the American Society of Clinical Oncology and used data from the TriNetX Global Health Research Network database. Scientists reviewed medical records from more than 12,000 patients diagnosed with seven types of solid tumors at stages 1 to 3.

Researchers compared cancer outcomes between patients using GLP-1 medications and those treated with another diabetes drug class known as DPP-4 inhibitors. The cancers included breast, lung, prostate, colorectal, liver, kidney and pancreatic cancer.

Lead author Marc David Orlando from the Cleveland Clinic’s Taussig Cancer Institute said the data showed significantly lower progression rates in several cancers among patients receiving GLP-1 therapy.

Strongest effects seen in breast and lung cancer

The most notable associations appeared in lung and breast cancer. According to coverage by NBC News, lung cancer patients using GLP-1 drugs were about 50 percent less likely to progress to stage 4 disease.

Among breast cancer patients, researchers observed an estimated 43 percent lower risk of cancer spread in those taking GLP-1 medications compared with the control group.

Lower rates of metastasis were reported in six of the seven cancers analyzed overall. Kidney cancer was the main exception, where GLP-1 treatment did not appear to reduce progression risk.

Why researchers are paying attention

Scientists have become increasingly interested in how obesity, insulin resistance and chronic inflammation affect cancer biology. Excess body weight is already linked to a higher risk of several cancers, including breast, colorectal and liver cancer.

GLP-1 medications work by mimicking a natural gut hormone involved in blood sugar regulation and appetite control. In addition to improving glucose metabolism, these drugs often produce substantial weight loss, which may indirectly influence cancer outcomes.

Researchers say the observed benefits could stem from multiple overlapping mechanisms, including reduced inflammation, improved insulin sensitivity, hormonal changes and lower body fat levels.

GLP-1 drugs continue to surge in popularity

The findings arrive as GLP-1 medications become some of the most widely discussed prescription drugs in the United States and Europe. A 2023 survey from health policy organization KFF found that about one in eight U.S. adults had used a GLP-1 drug for diabetes, weight loss or another chronic condition.

Nearly one in five adults reported having taken a GLP-1 medication at some point in their lives, reflecting the rapid mainstream adoption of drugs such as Ozempic, Wegovy and Mounjaro.

Important limitations remain

Researchers caution that the new findings do not prove GLP-1 drugs directly slow cancer growth. The study was observational, meaning other factors may partly explain the results.

Patients taking GLP-1 medications may also experience benefits from weight reduction, healthier blood sugar levels or better overall medical care, all of which can influence cancer progression independently.

Experts say randomized controlled trials will now be needed to determine whether GLP-1 therapies have a true anti-cancer effect and which patients might benefit most.

What this could mean in the future

For now, oncologists do not recommend using GLP-1 drugs specifically as cancer treatment outside clinical trials. However, the findings may eventually influence treatment planning for patients who have both obesity-related cancers and metabolic disease.

Researchers believe the overlap between obesity, diabetes and cancer will become increasingly important as rates of metabolic disorders continue rising globally. If future studies confirm the current findings, GLP-1 medications could eventually play a broader role not only in weight management, but also in long-term cancer care and prevention.